Metabolic biomarkers for predicting responsiveness to FGF-18 compound
AssigneeMerck Patent GmbH
InventorsChristoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist
Life of this patent
Estimating the term…
Loading patent…
AssigneeMerck Patent GmbH
InventorsChristoph H. Ladel, Hans Guehring, Anne-Christine Bay-Jensen, Morten Karsdal, Per Qvist
Estimating the term…
The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during treatment of a cartilage disorder. The present invention more particularly relates to specific proteins present in the blood, serum, synovial fluid or in the urine, which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to an FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the invention can be used in predicting the response to an FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment. It could be used for selecting/identifying subjects to be treated by intra-articular administration of an FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects.
A method for treating a subject having a cartilage disorder characterized by articular cartilage injury or loss of articular cartilage, with an FGF-18 compound, comprising the following steps:
A method for treating a subject having a cartilage disorder characterized by articular cartilage injury or loss of articular cartilage, with an FGF-18 compound, comprising the following steps:
Dependencies are inferred from the claim text.